Viral Vector Manufacturing Global Market Analysis 2024


The Global Viral Vector Manufacturing Market is projected to reach $1.71 billion by 2028, from a value of $0.59 billion in 2022, by registering a CAGR of 19.2% during the forecast period 2022-2028

SKU: ER1094 Category:
© Epson Research 2021
Share this infographic on
Published Year:
Forecast period:
Report Coverage:

Market Trends and analysis of the crucial market segments across North America, Europe, Asia Pacific and Rest of the World.

Report Format:

5 User License

$ 5,500

  • Access to Five users
  • Print upto 5 copies
  • PDF & Excel Formats

Corporate User License

$ 7,000

  • Unlimited users within company
  • Free Yearly update
  • PDF & Excel Formats

The Global Viral Vector Manufacturing Market is projected to reach $1.71 billion by 2028, from a value of $0.59 billion in 2022, by registering a CAGR of 19.2% during the forecast period. Effectiveness of viral vectors, availability of funding for the development of gene therapy, and ongoing research into viral vector-based gene & cell therapies are the major factors propelling the growth of the market. However, short shelf-life of viral vectors and high costs associated with gene therapy are hampering market growth. Moreover, rising prevalence of genetic disorders, potential applications in novel drug delivery approaches, and untapped potential in emerging markets are creating ample opportunities across the globe.

Recent Developments

In June 2022, Lonza and Adva Biotechnology Ltd. (“Adva”) have entered into a license agreement that will provide Adva access to core intellectual property enabling the expansion of automated bioreactors globally. Through the agreement, Lonza grants Adva a non-exclusive license to certain patents in its portfolio directed to smart automation and bioreactor control. Lonza and Adva have dismissed their ongoing litigation in the United States.

In October 2021, LEXEO Therapeutics and FUJIFILM Diosynth Biotechnologies announced a strategic collaboration to support the development and manufacturing of LEXEO’s adeno-associated virus (AAV)-mediated gene therapies.

In January 2021, Thermo Fisher Scientific announced around USD 880 million acquisition of Belgium-based Henogen SA, Novasep’s viral victor manufacturing business. Thermo Fisher is striving to foster its capabilities for cell and gene vaccines and therapies.

In April 2020, Merck KgaA and its subsidiary MilliporeSigma announced plans to spend USD 110 million to open a second viral vector facility at its Carlsbad, California facility. The projected expansion was expected to double the company’s gene therapy manufacturing capacity.

Competitive Landscape

Brammer Bio, Cobra Biologics, Finvector Vision Therapies, Fujifilm Holdings Corporation, Kaneka Eurogentec, Lonza, Massbiologics, Merck KGaA, Novasep, Oxford Biomedica, Regenxbio, Shape Therapeutics, Spark Therapeutics, Thermo Fisher Scientific Inc, and Uniqure are some of the major players in the global Viral Vector Manufacturing market.


1 Summary
2 Market Overview
2.1 Abstract
2.2 Research Sources
2.3 Research Findings
2.4 Assumptions
3 Market Dynamics
3.1 Drivers & Opportunities
3.2 Restraints & Threats
3.3 Regulatory Affairs
3.4 Supplychain Analysis
3.5 PORTERS Analysis
4 Competitive Landscape
5 Viral Vector Manufacturing Market by Type
5.1 Adeno-Associated Viral Vectors
5.2 Adenoviral Vectors
5.3 Cytomegalovirus
5.4 Retroviral Vectors
5.4.1 Lentiviral Vectors
5.4.2 Gamma-Retroviral Vectors
5.5 Herpes Simplex Virus Vectors
5.6 Pox Virus
6 Viral Vector Manufacturing Market by Disease
6.1 Veterinary Disease
6.1.1 Avian Influenza
6.1.2 Infectious Bronchitis
6.1.3 Marek’s Disease
6.1.4 Peste des Petits Ruminants (PPR) Disease
6.1.5 Other Veterinary Diseases Equine Influenza Fibromuscular Dysplasia (FMD) Newcastle Disease Rabies Swine Influenza
6.2 Human Disease
6.2.1 Cancer
6.2.2 Infectious Diseases Malaria Influenza Hepatitis
6.2.3 Genetic Disorders Tuberculosis Human Immunodeficiency Virus (HIV)
7 Viral Vector Manufacturing Market by Application
7.1 Vaccinology
7.1.1 Multivalent Vaccines
7.1.2 Multipathogen Vaccines
7.2 Gene Therapy
8 Viral Vector Manufacturing Market by End User
8.1 Research Institutes
8.2 Pharmaceutical and Biopharmaceutical Companies
8.3 Biotech Companies
9 Viral Vector Manufacturing Market by Regions
9.1 North America
9.2 Europe
9.3 Asia Pacific
9.4 Rest of the World
10 Company Profiles
10.1 Brammer Bio
10.2 Cobra Biologics
10.3 Finvector Vision Therapies
10.4 Fujifilm Holdings Corporation
10.5 Kaneka Eurogentec
10.6 Lonza
10.7 Massbiologics
10.8 Merck KGaA
10.9 Novasep
10.10 Oxford Biomedica
10.11 Regenxbio
10.12 Shape Therapeutics
10.13 Spark Therapeutics
10.14 Thermo Fisher Scientific Inc
10.15 Uniqure